

Index

ABANDONMENT

Rule 10b-5, loss causation, **11:9**

ABSTENTION

Generally, **23:3**

ABUSIVE DISCOVERY

Private Securities Litigation Reform Act of 1995, class actions, **3:8 to 3:8.90**

ABUSIVE LITIGATION

Private Securities Litigation Reform Act of 1995, sanctions for, **3:19**

ACCOUNTANTS

Insider trading, liability, **15:23**

ACCOUNTING

Sarbanes-Oxley Act, management assessment of internal accounting controls—Section 404, **5A:14**

AIDING AND ABETTING

Insider trading, Stoneridge decision, **15:9, 15:17**

Rule 10b-5, constitutional law, **9:8**

ANALYSTS

Insider trading, fraud on the market theory in actions against analysts, **15:11**

Rule 10b-5, fraud-on-the-market theory, **10:30.10**

AOL-SIMPSON DECISION

Insider trading, Ninth Circuit, expanding liability of secondary actor, **15:28**

APPRAISAL

Interference with market for corporate control, **16:8**

APPROVAL

Class actions, judicial approval of settlement, **25:3**

ARBITRATION

Racketeer influenced and corrupt organizations, **22:12 to 22:14**

ARRANGEMENTS

Monitoring, institutional investors, **25:1.30**

8220Pay to play, 8221 selection of interim lead plaintiff, **25:1.20**

ARTIFICIAL INFLATION

Rule 10b-5, fraud on the market and, **11:11**

ASSIGNMENT

Section 10(b) claims, **26:1, 26:2**

“AT LEAST AS LIKELY” STANDARD

Supreme Court, pleading requirements for PLS., **3:11.70, 3:11.80**

ATTORNEY-CLIENT PRIVILEGE

Sarbanes-Oxley Act, securities fraud, new statutory duty to disclose client confidences, **5C:3, 5C:5**

ATTORNEYS

Fees. See **Attorneys’ Fees** (this index)

Insider trading, liability, **15:24**

Non-lead counsel, issues with and other actors seeking payment from the common fund, **25:4.40**

Private Securities Litigation Reform Act of 1995, sanctions, **3:19**

Sarbanes-Oxley Act (SOX) (this index)

ATTORNEYS’ FEES

Generally, **21:1, 21:2**

Class actions, **25:4 to 25:4.30**

Lodestar versus percentage-of-fund recovery in class action, **25:4.10**

Objecting to attorneys’ fees, **25:4.20**

Presumption of reasonableness to agreed-upon fees in class action, **25:4.30**

ATTORNEYS' FEES—Cont'd

Racketeer influenced and corrupt organizations, **22:9**

AUCTIONING

Class actions, selection of class counsel through auctioning, **25:6, 25:8**

AUDITS AND AUDITORS

Pleading scienter for outside auditors, **24:5**

Sarbanes-Oxley Act (SOX) (this index)

AUTOMATIC STAY

Sarbanes-Oxley Act of 2002, debtor-company in bankruptcy, **5D:3**

AWARENESS OF PLAINTIFF

Insider trading, Stoneridge decision, **15:16 to 15:20**

BALANCE OF INTERESTS TEST

International securities regulation, **27:5**

BANKRUPTCY AND SECURITIES FRAUD

Sarbanes-Oxley Act (SOX) (this index)

BARS

Sarbanes-Oxley Act, officer and director bars—Section 305, **5A:10**

BENEFIT OF THE BARGAIN

Instructions to jury, Section 10(b) of Securities Exchange Act of 1934, **24:47**

Rule 10b-5, **13:3, 14:65**

BROKERS

Implied actions and remedies, Section 15 of Securities Exchange Act of 1934, **19:8**

CAUSATION

Instructions to jury, Section 10(b) of Securities Exchange Act of 1934, **24:45**

Loss causation. See **Private Securities Litigation Reform Act of 1995** (this index)

Proxy fraud. See **Proxy Fraud** (this index)

Rule 10b-5. See **Rule 10b-5** (this index)
Section 11, Securities Act of 1933, **6:25**

CAUSATION—Cont'd

Securities Exchange Act of 1934, **8:4, 8:16**

CEO

Sarbanes-Oxley Act, certification requirements, **5A:3, 5B:4**

CERTIFICATION

Barrier to class certification, **24:15**

Class actions

generally, **24:13**

barrier, **24:15**

loss causation, **24:13.20**

materiality, **24:13.10**

Sarbanes-Oxley Act (SOX) (this index)

CFO

Sarbanes-Oxley Act, certification requirements, **5A:3, 5B:4**

CHALLENGES

Event studies in securities fraud litigation, **25B:5**

CHARTS

Instructions to jury, **24:26, 24:27**

CHURNING

Insider trading. See **Insider Trading** (this index)

CIVIL ACTIONS

Sarbanes-Oxley Act enhancement of private civil liability. See **Sarbanes-Oxley Act (SOX)** (this index)

CLASS ACTION FAIRNESS ACT

Generally, **25A:1**

CLASS ACTIONS

Generally, **25:1 et seq.**

Advertising 8220investigations, 8221 solicit lead plaintiffs, **25:1.40**

Attorneys' fees, **25:4 to 25:4.30**

Auctioning, selection of class counsel through, **25:6, 25:8**

Bankruptcy and securities fraud, **5D:4**

Barrier to class certification, **24:15**

Certification of class

generally, **11A:17 et seq., 24:13**

barrier, **24:15**

INDEX

CLASS ACTIONS—Cont'd

- Certification of class—Cont'd
 - loss causation, **24:13.20**
 - materiality, **24:13.10**
 - “mismatch” defense, **24:13.30**
 - Morrison case, effect on, **25:9**
 - rebutting reliance, **24:13.30**
 - reliance, rebutting, **24:13.30**
- Class Action Fairness Act, **25A:1**
- Counsel, selection of, **25:6**
- Cy Pres awards, **25:3.20**
- Fraud-on-the-theory, **11A:17.10**, **11A:17.20**
- Independent approval of settlement, **25:3.10**
- Judicial approval of settlement, **25:3**
- Lead plaintiff, selection of, **25:1 et seq.**
- Lodestar attorney fees versus percentage-of-fund recovery in class action, **25:4.10**
- Materiality, “plausible” allegation, **11A:17.40**
- Monitoring arrangements, institutional investors, **25:1.30**
- Non-lead counsel, issues with and other actors seeking payment from the common fund, **25:4.40**
- Objecting to attorneys’ fees, **25:4.20**
- 8220Pay to play8221 arrangements, **25:1.20**
- Presumptions
 - reasonableness to agreed-upon fees, **25:4.30**
 - reliance, rebutting presumption, **11A:17.40**
- Private Securities Litigation Reform Act of 1995. See **Private Securities Litigation Reform Act of 1995** (this index)
- Publication of settlement, **25:2**
- Rebutting
 - fraud-on-the-theory, **11A:17.10**
 - reliance, presumption of, **11A:17.40**
- Reliance, rebutting presumption, **11A:17.40**
- Rule 10b-5, rebuttal of fraud-on-the-market theory, class certification, **10:30.15**
- Sarbanes-Oxley Act (SOX), **5D:4**

CLASS ACTIONS—Cont'd

- Securities Litigation Uniform Standards Act of 1998
 - actions that are joined, consolidated, or otherwise proceeding as a single action, **5:6.50**
 - defined class actions, **5:6**
 - state court, federal class actions in, **5:8.70**
- Security for costs, **25:5**
- Selection of counsel, **25:6**
- Selection of interim lead plaintiff
 - advertising 8220investigations,8221 solicit lead plaintiffs, **25:1.40**
 - monitoring arrangements, institutional investors, **25:1.30**
 - 8220Pay to play8221 arrangements, **25:1.20**
- Settlement, **25:2**, **25:3**, **25:3.10**
- Third Circuit task force, recommendations, **25:7**

COLLECTIVE SCIENTER

- Tellabs case, **24:55**

COMMON LAW

- Loss causation, common law fraud, **11A:20**
- Rule 10b-5. See **Rule 10b-5** (this index)
- Sarbanes-Oxley Act, attorney’s duty to blow whistle on securities fraud, **5C:2**
- Section 11, Securities Act of 1933, **6:7**

COMMON SECONDARY ACTORS

- Insider trading, Stoneridge decision, **15:18**

COMPENSATION

- Forfeiture of executive compensation upon restatements—Section 304, **5A:9**

CONDOMINIUMS

- Investment contracts, **1:6**

CONDUCT OR MISCONDUCT

- Sarbanes-Oxley Act, conduct rules for attorneys—Section 307, **5A:12**

“CONDUCT” TEST

- Internet, extraterritorial subject matter jurisdiction, **28:3**, **28:7**, **28:8**

CONFIDENTIAL SOURCES

- Circuit survey and effect of Tellabs, **24:53.10**
- Discovery, **24:54, 24:54.10**
- Documents from, **24:53.20**
- Pleading after Tellabs, **24:52.50, 24:53, 24:55**
- Private investigators, **24:53.30**
- Rule 26 discoverability of identities, **24:54.10**

CONFIDENTIAL WITNESSES

- Securities fraud pleading, **24:53**

CONFLICT OF LAWS

- Sarbanes-Oxley Act, state attorney confidentiality standards in conflict with SEC's regime, **5C:5**

CONGRESSIONAL INTENT

- Private Securities Litigation Reform Act of 1995, loss causation, **11A:4**

CONSENT

- Class actions, approval of settlement, **25:3, 25:3.10**

CONSEQUENTIAL DAMAGES

- Rule 10b-5. See **Rule 10b-5** (this index)

CONSTITUTIONAL LAW

- Event studies in securities fraud litigation, **25B:2**
- Rule 10b-5. See **Rule 10b-5** (this index)

CONSTRUCTION AND INTERPRETATION

- Private Securities Litigation Reform Act of 1995 (this index)

CONSUMER FINANCIAL PROTECTION BUREAU

- Dodd-Frank, **5E:4**

CONTRACT VOIDANCE

- Generally, **23:6**

CONTRIBUTION AND INDEMNIFICATION

- Generally, **20:1 et seq.**
- Basics of D&O insurance, **20:29**
- Claim procedure, **20:8**
- Common provisions in D&O insurance, **20:30**

CONTRIBUTION AND INDEMNIFICATION—Cont'd

- Director and officer (D&O) insurance and securities fraud
 - basics of D&O policy, **20:29**
 - common provisions, **20:30**
 - settlement, **20:32**
 - "tower," **20:31**
- Implied right to contribution. See **Rule 10b-5** (this index)
- Insurance
 - generally, **20:28**
 - basics of D&O insurance, **20:29**
 - director and officer (D&O) insurance and securities fraud, above
 - fraud by directors and officers, **20:29**
- Joint tortfeasors, **20:4**
- Judicial power to create, **20:3**
- Rule 10b-5. See **Rule 10b-5** (this index)
- Settlement
 - D&O insurance, **20:32**
 - effect on contribution, **20:5, 20:27**
 - "Tower," D&O insurance, **20:31**

CORNERSTONE RESEARCH

- Class actions under PSLRA, statistics, **4:3**

CORPORATE FINANCE THEORY

- Private Securities Litigation Reform Act of 1995, loss causation, **11A:8**

CORPORATE OFFICERS AND DIRECTORS

- Insider trading, liability, **15:25**

COSTS AND EXPENSES

- Generally, **21:1, 21:2**
- Attorneys' fees. See **Attorneys' Fees** (this index)
- Class actions, security for costs, **25:5**
- Racketeer influenced and corrupt organizations, **22:9**
- Section 16, Securities Exchange Act of 1934, **8:13**

COVER

- Rule 10b-5, Tenth Circuit, **14:52**

CREDIT DEFAULT SWAPS

- FINFA rules, **26A:1**

INDEX

CRIMINAL LAW

Sarbanes-Oxley Act, reliance on criminal law, **5A:25**

CRYPTOCURRENCIES

Regulation of, **2:6**

CY PRES AWARDS

Class actions, **25:3.20**

DAMAGES, LAW OF

Generally, **1:2, 29:1, 29:2**

For detailed matters, see more specific entries throughout this index

Securities litigation, **1:4**

DAMAGES FORMULA

Private Securities Litigation Reform Act of 1995, **3:14.30 to 3:14.50**

DAMAGES FOR VIOLATIONS OF SECTION 12, SECURITIES ACT OF 1933

Conduct prohibited by section 12(a)(1), **7:5**

Conduct prohibited by section 12(a)(2), **7:6**

a 8220prospectus8221 and the 8220public offering8221 limitation, **7:7**

Contribution and indemnification, **7:15**

Introduction to damages under section 12, **7:9-7:13**

Introduction to damages under section 12 contribution and indemnification, **7:14**

Introduction to express remedies, **7:1**

8220Sellers8221 under section 12 and persons liable, **7:2**

those who pass title, **7:3**

those who successfully solicit, **7:4**

Statutes of limitations for section 12(a)(2), **7:16**

Timeliness bars applicable to section 12 claims, **7:8**

DEALERS

Implied actions and remedies, Section 15 of Securities Exchange Act of 1934, **19:8**

DECEPTIVE CONDUCT PLUS PLAINTIFF AWARENESS

Insider trading, Stoneridge decision, **15:16 to 15:20**

DEFENSES

Section 11, Securities Act of 1933, **6:4**

DEFINITION

Security, **1:5**

DEPOSITIONS

Expert witnesses, **24:23, 24:24**

Instructions to jury, **24:28**

DIRECT MARKET REPERCUSSION THEORY

Rule 10b-5, Second Circuit, **14:10**

DIRECTOR AND OFFICER (D&O) INSURANCE

Ancillary sources of damages, **20:29 et seq.**

DISCIPLINE

Implied actions and remedies, Section 6(b) of Securities Exchange Act of 1934, **19:3**

DISCLOSURE

Duty, materiality, **10:27.60**

Implied actions and remedies, Sections 11(d)(2) and 17(a) of Securities Exchange Act of 1934, **19:5**

Sarbanes-Oxley Act (SOX) (this index)

DISCOVERY

Generally, **24:16**

Depositions. See **Depositions** (this index)

Expert witnesses, **24:22 to 24:24**

Securities Litigation Uniform Standards Act of 1998, stay, **5:13**

Tellabs case, **24:53**

DISGORGEMENT

Rule 10b-5. See **Rule 10b-5** (this index)

DIVIDENDS

Section 16, Securities Exchange Act of 1934, **8:11**

DODD-FRANK ACT (2010)

Generally, **5E:1 to 5E:5**

DODD-FRANK ACT (2010)—Cont'd

Antifraud measures, security-based swaps, **5E:2**
 Consumer financial protection bureau, **5E:4**
 Extraterritoriality of securities fraud litigation, **5E:5**
 Security-based swaps, antifraud measures, **5E:2**
 Whistleblowers, **5E:3**

DUAL INQUIRY TEST

Ninth Circuit, pleading scienter after Tellabs, **3:11.130**

DURA PHARMACEUTICALS CASE

Private Securities Litigation Reform Act of 1995 (this index)

DUTY TO DISCLOSE

Materiality, rule 10b-5, **10:27.60**

ECONOMIC LOSS

Private Securities Litigation Reform Act of 1995, loss causation, **11A:7**, **11A:8**

“EFFECTS” TEST

Internet, extraterritorial subject matter jurisdiction, **28:4**, **28:7**, **28:8**

ELECTION

Rule 10b-5, rescission or rescissory damages, **14:51**

ELECTRONIC DELIVERY

Federal securities regulation, **5:14**

EMPLOYEE STOCK OPTIONS

Section 16, Securities Exchange Act of 1934, **8:10**

ENFORCEMENT OF SECURITIES LAWS

FINFA and role of SROs, **26A:2**

ENRON SCANDAL

Insider trading, Stoneridge decision, **15:20**

Private Securities Litigation Reform Act of 1995, laxity, **4:4**

EQUITABLE RELIEF

Racketeer influenced and corrupt organizations, **22:9**

“ETHICS” CODE

Sarbanes-Oxley Act, ethics code for financial officers—Section 406, **5A:15**

EVENT STUDIES IN SECURITIES FRAUD LITIGATION

Generally, **25B:1**

Accounting for “tangle of factors,” **25B:4**

Acknowledgment of “tangle of factors,” **25B:4**

Analysis methodology, **25B:3**

Challenging reliability, **25B:5**

Class certification, **25B:6**

Constitutional law, **25B:2**

Dispositive role, Seventh Amendment, **25B:2**

Efficiency of market, **25B:7**

Impact of market, **25B:7**

Loss causation, **11A:16**

Market efficiency, **25B:7**

Market impact, **25B:7**

Methodology, **25B:3**

Potential Seventh Amendment problems, **25B:2**

Questions of market impact and efficiency, **25B:7**

Recognition of “tangle of factors,” **25B:4**

Reliability challenge, **25B:5**

Rule 10b-5 claims, **25B:6**

Section 10(b) of Securities Exchange Act, **25B:6**

Section 11 of Securities Act of 1933, **25B:8**

Seventh Amendment problems, **25B:2**

Summary judgment, **25B:9**

“Tangle of factors,” **25B:4**

EVIDENCE

Loss causation, proving, **3:12.10**, **11A:16**

EXHIBITS

Instructions to jury, **24:26**, **24:27**

EXPENSES

Costs and expenses. See **Costs and Expenses** (this index)

INDEX

EXPERT WITNESSES

Generally, **24:19 et seq.**
Complaints, **24:2.50**
Depositions, **24:23, 24:24**
Disclosure, **24:22 to 24:24**
Instructions to jury, **24:29, 24:30**
Loss causation, **11A:16**
Private Securities Litigation Reform Act of 1995, damages formula, **3:14.50**
Types of experts, **24:21**

EXTENSION OF CREDIT

Implied actions and remedies. See **Implied Actions and Remedies** (this index)

EXTERNAL MARKET FORCES

Rule 10b-5, Seventh Circuit, **14:39**

EXTRATERRITORIAL JURISDICTION

Dodd-Frank, **5E:5**
International securities regulation. See **International Securities Regulation** (this index)

FAIR SHARE RULE

Private Securities Litigation Reform Act of 1995, proportionate liability, **3:14**

FIDUCIARY DUTY

Rule 10b-5, **10:7**

FILING

Implied actions and remedies, Section 13(a) of Securities Exchange Act of 1934, **19:7**
Private Securities Litigation Reform Act of 1965, NERA and cornerstone research securities, **4:3**

FINANCIAL EXPERTS

Sarbanes-Oxley Act, audit committee financial experts—Section 407, **5A:16**

FINANCIAL INDUSTRY REGULATORY AUTHORITY (FINRA)

See **FINRA** (this index)

FINANCIAL OFFICERS

Sarbanes-Oxley Act, ethics code—Section 406, **5A:15**
SROs, role in enforcing securities laws, **26A:2**

FINRA

Claims involving FINRA members, **26A:1, 26A:2**
Credit default swaps under FINFA rules, **26A:1**
Customers and credit default swaps under FINFA rules, **26A:1**

FORCED SALE

Sarbanes-Oxley Act of 2002, bankruptcy and securities fraud, **5D:2**

FORCED SELLER DOCTRINE

Material misrepresentations, Section 11 and Section 12 claims, **14A:2**

FOREIGN CUBED CASES

Rule 10b-5, extraterritorial application, **10:2.50, 10:2.60**

FORFEITURES

Sarbanes-Oxley Act of 2002, forfeiture of executive payments upon restatements—Section 304, **5A:9**

FORMULA FOR DAMAGES

Section 11, Securities Act of 1933. See **Section 11, Securities Act of 1933** (this index)

FRAUD

Confidential witnesses, securities fraud pleading, **24:53**
Event studies. See **Event Studies in Securities Fraud Litigation** (this index)
Insider trading, Stoneridge decision, **15:13, 15:16 to 15:20**
Proxy fraud. See **Proxy Fraud** (this index)
Section 11, Securities Act of 1933, fraud against mutual funds, **6:4.10**
Securities fraud, generally. **Sarbanes-Oxley Act (SOX)** (this index)

FRAUD BY HINDSIGHT

Tellabs case, **24:57**

**FRAUD-CREATED-THE-MARKET
THEORY**

Rule 10b-5, **10:30, 10:31 et seq.**

FRAUD ON THE MARKET

Analysts, actions against, **15:11**
 Artificial inflation, Rule 10b-5, **11:11**
 Endorsement by Supreme Court, **13:17**
 Insider trading, **15:10, 15:11**
 Loss causation, **11A:9, 11A:15.10**
 Measure of damages, uniformity, **13:16**
 Private Securities Litigation Reform Act
 of 1995, limitation of scope in Dura
 Pharmaceuticals court decision,
11A:9
 Rule 10b-5, **10:30.10, 10:30.15,**
10:30.50, 11:11, 13:16
 Stoneridge decision, **15:10**

GLOSSARY

Generally, **App 4**

GOOD WILL

Section 11 and Section 12, Securities
 Act of 1933, misrepresentation in
 registration statements, **14A:1**

GROUP PLEADING

Tellabs, **24:55**

IMPLIED ACTIONS AND REMEDIES

Generally, **19:1 et seq.**
 Brokers and dealers, Section 15 of Securities
 Exchange Act of 1934, **19:8**
 Discipline of members, Section 6(b) of
 Securities Exchange Act of 1934,
19:3
 Disclosure requirements, Sections
 11(d)(2) and 17(a) of Securities
 Exchange Act of 1934, **19:5**
 Extension of credit
 Rule 10b-16, **19:10**
 Section 7(c) of Securities Exchange
 Act of 1934, **19:4**
 Filing requirements, Section 13(a) of
 Securities Exchange Act of 1934,
19:7
 Obstruction of filings, Section 20(c) of
 Securities Exchange Act of 1934,
19:9

**IMPLIED ACTIONS AND REMEDIES
—Cont’d**

Reporting requirements, Section 12(b)
 and (f) of Securities Exchange Act
 of 1934, **19:6**
 Rule 10b-5. See **Rule 10b-5** (this index)
 Section 17(a), **19:1, 19:2**

INDEMNIFICATION

Contribution and indemnification. See
Contribution and Indemnifica-
tion (this index)

INFERENCES

Tellabs case, scienter, **24:56 et seq.**

INFORMANTS

Sarbanes-Oxley Act, no retaliation
 against informants—Section 1107,
5A:21

INITIAL COIN OFFERINGS

Regulation of, **2:6**

INJUNCTIONS

Generally, **23:2**
 Interference with market for corporate
 control, tender offers, **16:4**

IN LIMINE MOTIONS

Generally, **24:18**

**IN RE CHARTER
COMMUNICATIONS**

Insider trading, Eighth Circuit, **15:27**

INSIDER TRADING

Generally, **15:1 et seq.**
 Accountant liability, **15:23**
 Analysts, actions against, **15:11**
 Attorney liability, **15:24**
 Central Bank decision, **15:32**
 Churning, **15:4**
 Common secondary actors, **15:18**
 Congressional restatement of scheme /
 secondary liability, **15:30**
 Corporate officer liability, **15:25**
 “Creationism” test for scheme / second-
 ary liability, **15:31**
 Deceptive conduct plus plaintiff aware-
 ness, **15:16 to 15:20**

INDEX

INSIDER TRADING—Cont'd

- Drafting materials used to effect fraudulent transactions, attorney liability, **15:24**
- Duty to disclose, absence of, **15:3**
- Eighth Circuit, In Re Charter Communications decision, **15:27**
- Fifth Circuit
 - pleading scienter after Tellabs, **15:10, 24:10**
 - secondary liability issue, **15:29**
- First Circuit, pleading scienter after Tellabs, **24:8**
- Fraud on the market, **15:10, 15:11**
- Implied private rights of action under Section 10(b), **15:12**
- Janus decision, **15:32**
- Lorenzo decision, **15:32**
- Loss causation, pleading, **24:12, 24:15**
- Misrepresentation or omission in audit opinions, accountant liability, **15:23**
- Ninth Circuit, AOL-Simpson decision, expanding liability of secondary actor, **15:28**
- Outside counsel liability, **15:24**
- Primary liability after Stoneridge decision, **15:22**
- Professional liability under Sarbanes-Oxley, **15:6**
- Reaffirming bar on aiding and abetting liability, **15:9**
- Reliance, **15:10**
- Reviewing materials used to effect fraudulent transactions, attorney liability, **15:24**
- Revising materials used to effect fraudulent transactions, attorney liability, **15:24**
- Sarbanes-Oxley. See **Sarbanes-Oxley Act (SOX)** (this index)
- Scheme / secondary liability, **15:30, 15:31**
- Scienter** (this index)
- SEC aiding and abetting enforcement actions, **15:17**
- Secondary liability, **15:5, 15:9**
- Secondary liability issue
 - Eighth Circuit, In Re Charter Communications decision, **15:27**

INSIDER TRADING—Cont'd

- Secondary liability issue—Cont'd
 - Fifth Circuit, **15:29**
 - Ninth Circuit, AOL-Simpson decision, **15:28**
 - scheme / secondary liability, **15:30 to 15:32**
 - Stoneridge decision, below
 - Supreme Court, **15:7 et seq.**
- Seventh Circuit, pleading scienter after Tellabs, **24:11**
- State court litigation, **15:19**
- Stoneridge decision
 - generally, **15:7**
 - aiding and abetting liability, **15:9**
 - analysis of impact, **15:14, 15:15**
 - Central Bank decision, **15:32**
 - common secondary actors, **15:18**
 - deceptive conduct plus plaintiff awareness, **15:16 to 15:20**
 - Enron litigation, **15:20**
 - factual background, **15:8**
 - fraud on the market, **15:10**
 - implied private rights of action under Section 10(b), **15:12**
 - Janus decision, **15:32**
 - Lorenzo decision, **15:32**
 - policy implications in securities fraud action, **15:13**
 - primary liability following decision, **15:22**
 - reaffirming bar on aiding and abetting liability, **15:9**
 - reliance, **15:10**
 - SEC aiding and abetting enforcement actions, **15:17**
 - secondary actor liability, **15:9**
 - secondary liability, generally, **15:7 et seq.**
 - state court litigation, **15:19**
- Supreme Court
 - Central Bank decision, **15:26, 15:32**
 - Janus decision, **15:32**
 - Lorenzo decision, **15:32**
 - secondary liability guidance.
 - Stoneridge decision, above
 - Stoneridge decision, **15:32**
- Third Circuit, pleading scienter after Tellabs, **24:9**

INSTITUTIONAL INVESTORS

- Private Securities Litigation Reform Act of 1995, class actions, **3:3, 3:6**
- Selection of an interim lead plaintiff, monitoring arrangements, **25:1.30**

INSTRUCTIONS TO JURY

- Generally, **24:25 et seq.**
- Benefit of the bargain, Section 10(b) of Securities Exchange Act of 1934, **24:47**
- Causation, Section 10(b) of Securities Exchange Act of 1934, **24:45**
- Charts and summary exhibits, **24:26, 24:27**
- Conflicting expert testimony, **24:30**
- Damages; caution against inference from instruction, **24:31**
- Depositions, **24:28**
- Expert witnesses, **24:29, 24:30**
- Joint and several liability, **24:34**
- Materiality, **24:50**
- Multiple defendants, caution against, **24:33**
- Multiple recovery, caution against, **24:32**
- Rescissionary measure, Section 10(b) of Securities Exchange Act of 1934, **24:48**
- Section 10(b) of Securities Exchange Act of 1934
 - generally, **24:46 et seq.**
 - benefit of the bargain measure, **24:47**
 - causation, **24:45**
 - general measure, **24:46**
 - rescissionary measure, **24:48**
 - uniform instruction, **24:49**
- Section 11, Securities Act of 1933. See **Section 11, Securities Act of 1933** (this index)
- Section 12, Securities Act of 1933, **24:42 to 24:44**
- Uniform instruction, Section 10(b) of Securities Exchange Act of 1934, **24:49**

INSURANCE

- See **Contribution and Indemnification** (this index)

INTEREST

- Generally, **21:1, 21:3**
- Section 16, Securities Exchange Act of 1934, **8:12**

INTERFERENCE WITH MARKET FOR CORPORATE CONTROL

- Generally, **16:1 et seq.**
- Appraisal remedies, **16:8**
- Federal and state law remedies, relationship between, **16:7**
- Injunctions, tender offers, **16:4**
- Minority shareholders, remedies of, **16:6**
- Proxy solicitation relief, **16:2**
- Rescission, **16:5**
- Tender offers, **16:3, 16:4**

INTERIM LEAD PLAINTIFF

- Selection
 - monitoring arrangements, institutional investors, **25:1.30**
 - 8220Pay to play8221 arrangements, **25:1.20**

INTERNATIONAL SECURITIES REGULATION

- Generally, **27:1 et seq.**
- Balance of interests test, **27:5**
- Congressional response to Morrison decision, **10:2.60**
- Criticisms of extraterritorial jurisdiction, **27:1 to 27:6**
- Extraterritorial jurisdiction, **27:1 et seq.**
- Injury to United States, **27:6**
- Legislative intent, **27:3, 27:7**
- Morrison, evolution of and extraterritorial reach of Rule 10b-5, **10:2.70**
- Reliance on international law, **27:4, 27:8**
- Rule 10b-5, application by Second Circuit, **10:2.50, 27:10**
- Statutory construction, **27:3, 27:7**

INTERNET

- Generally, **5:14, 5:15, 28:1 et seq.**
- “Conduct” test, extraterritorial subject matter jurisdiction, **28:3, 28:7, 28:8**
- Cryptocurrencies, regulation of, **2:6**
- Cyberspace securities transactions, **28:6**
- “Effects” test, extraterritorial subject matter jurisdiction, **28:4, 28:7, 28:8**

INDEX

INTERNET—Cont'd

- Extraterritorial subject matter jurisdiction, **28:2 to 28:4**
- Initial coin offerings, regulation of, **2:6**
- Jurisdiction, **28:1 et seq.**
- Personal jurisdiction, **28:5**

INTRODUCTION

- Generally, **1:1 et seq.**

INVESTMENT CONTRACTS

- Condominiums, **1:6**

JOINT AND SEVERAL LIABILITY

- Private Securities Litigation Reform Act of 1995, **3:14.10**

JOINT TORTFEASORS

- Contribution and indemnification, **20:4**
- Instructions to jury, **24:34**

JURISDICTION

- Internet. See **Internet** (this index)
- Securities laws, **1:3.10**

JURY INSTRUCTIONS

- Instructions to jury. See **Instructions to Jury** (this index)

LANGUAGE

- Private Securities Litigation Reform Act of 1995, Supreme Court's interpretation of language in Act, **11A:2**

LAXITY

- Enron scandal, Private Securities Litigation Reform Act, **4:4**

LEGISLATIVE HISTORY

- Private Securities Litigation Reform Act of 1995, loss causation, **11A:3**

LIABILITIES

- Securities Act of 1993
section 11 liability, elements, **6:3**

LIMITATION OF ACTIONS

- Rule 10b-5, **9:14 et seq.**
- Sarbanes-Oxley Act. See **Sarbanes-Oxley Act (SOX)** (this index)
- Section 10(b), Securities Exchange Act of 1934, **9:18**
- Section 16, Securities Exchange Act of 1934, **8:14.50**

LIMITED LIABILITY COMPANIES

- Generally, **2:1 et seq.**
- Attributes, **2:3, 2:4**
- Predictability, **2:5**
- Supreme Court standards for defining security, **2:2, 2:4**

LITIGATION

- Generally, **24:1 et seq.**
- Artificially inflating the value of a security, **24:3.10**
- Investigating and preparing for securities litigation, **24:1.10**
 - accessing internal company information, **24:1.30**
 - examining publicly available material, **24:1.20**
- The dissipation of that artificial inflation, **24:3.20**
 - inflationary loss as a result of the company's collapse, **24:3.50**
 - inflationary loss through market forces, **24:3.40**
 - inflationary loss upon a corrective disclosure and a drop in stock value, **24:3.30**

LOAN LOSS RESERVES

- Section 11 and Section 12, Securities Act of 1933, material misrepresentation in registration statements, **14A:1**

LOANS

- Sarbanes-Oxley Act, prohibition on loans to executive officers and directors, **5A:6**

LOSS CAUSATION

- Insider trading, pleading, **24:12, 24:15**
- Private Securities Litigation Reform Act of 1995** (this index)
- Rule 10b-5. See **Rule 10b-5** (this index)
- Short selling and securities litigation, **24:12.10**

MANAGEMENT

- Sarbanes-Oxley Act, management assessment of internal accounting controls—Section 404, **5A:14**

**MARKET IMPACT AND
EFFICIENCY**

Event studies in securities fraud litigation, **25B:7**

MARKET MANIPULATION

Listed stock manipulations, **8:3 to 8:5**
Rule 10b-5, auction rate securities,
10:31.90

MATERIALITY

Generally, **18:1 et seq.**
Class actions, “plausible” allegation,
11A:17.40
Class certification, **24:13.10**
Instructions to jury, **24:50**
Private Securities Litigation Reform Act
of 1995, **3:9**
Rule 10b-5. See **Rule 10b-5** (this index)
Soft information, **18:3**
Subjective vs. objective falsehoods, **18:4**
Supreme Court and statistical significance,
18:5
Supreme Court definition, **18:2**
Virginia Bankshares, **18:3**

**MATERIALIZATION OF RISK
THEORY**

Loss causation, **11A:15.20**

MERITLESS LITIGATION

Private Securities Litigation Reform Act
of 1995, sanctions, **3:19**

METHODOLOGY

Event studies in securities fraud litigation,
25B:3

MINORITY SHAREHOLDERS

Interference with market for corporate
control, **16:6**

MISAPPROPRIATION

Rule 10b-5, **10:11**

MISREPRESENTATION

Section 11 and Section 12, Securities
Act of 1933, good will and loan
loss reserves misrepresented in
registration statements, **14A:1**

**MODEL COMPLAINT UNDER
PSLRA**

Generally, **3:20, 3:21**

MONITORING ARRANGEMENTS

Selection of an interim lead plaintiff,
institutional investors, **25:1.30**

MOTIONS IN LIMINE

Generally, **24:18**

MOTIVE

Pleading scienter after Tellabs, independent
method to establish scienter,
3:11.120

MULTIDISTRICT TRANSFERS

Pretrial, **24:51**

MULTIPLE DEFENDANTS

Instructions to jury, **24:33**

MULTIPLE RECOVERY

Instructions to jury, **24:32**

MUTUAL FUNDS

Section 11, Securities Act of 1933,
6:4.10

**NATIONAL ECONOMIC RESEARCH
ASSOCIATES**

Class actions under PSLRA, statistics,
4:3

NEGATIVE CAUSATION

Section 11, Securities Act of 1933, **6:28,**
6:31

**NERA AND CORNERSTONE
RESEARCH**

Class actions under PSLRA, statistics,
4:3

OBSTRUCTION OF FILINGS

Implied actions and remedies, Section
20(c) of Securities Exchange Act of
1934, **19:9**

OPPORTUNITY

Pleading scienter after Tellabs, independent
method to establish scienter,
3:11.120

OUT-OF-POCKET

Rule 10b-5, **13:4 to 13:6**

INDEX

8220PAY TO PLAY8221

Arrangements, selection of interim lead plaintiff, **25:1.20**

PENSION BLACKOUT PERIODS

Sarbanes-Oxley Act, insider trades during pension blackout periods—
Section 306, **5A:11, 5B:6**

PLAINTIFF

Advertising 8220investigations,8221
solicit lead plaintiffs, **25:1.40**
Monitoring arrangements, institutional
investors, **25:1.30**
8220Pay to play8221 arrangements,
25:1.20

PLEADINGS

Generally, **24:2**
Adequate theories of loss, **24:3**
Confidential witness, securities fraud
pleadings, **24:53**
Experts in complaints, **24:2.50**
Loss theories, **24:3**
Outside auditors, scienter, **24:5**
Private Securities Litigation Reform Act
of 1995. See **Private Securities
Litigation Reform Act of 1995**
(this index)
Tellabs case, **24:52.50, 24:53, 24:55**

POSTJUDGMENT INTEREST

Generally, **21:1, 21:3**

PRACTICE

Generally, **24:1 et seq.**

PREEMPTION

Federal securities regulation, generally,
5:1
Sarbanes-Oxley Act, attorney disclosure
requirements, new SEC profes-
sional standards, **5C:6**

PREJUDGMENT INTEREST

Generally, **21:1, 21:3**

PRESUMPTIONS

Attorneys' fees in class action,
reasonableness to agreed-upon fees,
25:4.30
Reliance, rebutting presumption of in
class action, **11A:17.40**

PRESUMPTIONS—Cont'd

Rule 10b-5, **10:30**

PRIVATE ACTIONS

Insider trading, Stoneridge decision,
15:12
Sarbanes-Oxley Act (SOX) (this index)

PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Generally, **3:1 et seq., 4:1 et seq.**
Abusive discovery, class actions, **3:8 to
3:8.90**
Abusive litigation, sanctions for, **3:19**
Allegations, Tellabs case, **3:11.10**
“At least as likely” standard, pleading
requirements, **3:11.70, 3:11.80**
Attorney sanctions for pursuing merit-
less litigation, **3:19**
Causation of loss. Loss causation, below
Class actions
generally, **3:2 et seq., 4:1 et seq.**
abusive discovery, **3:8 to 3:8.90**
auctioning, selection of class counsel
through, **25:6, 25:8**
certification, loss causation, **11A:17 et
seq., 11A:18, 24:14, 24:15**
empirical analysis, **4:1 et seq.**
fraud-on-the-market theory,
11A:17.10, 11A:17.20
grundfest and Perino study, **4:2**
institutional investors, **3:3, 3:6**
loss causation, **11A:17 et seq.,
11A:18, 24:14, 24:15**
loss causation and limitation of dam-
ages, **3:14.40**
materiality, “plausible” allegation,
11A:17.40
NERA and cornerstone research secu-
rities statistics, **4:3**
professional and lead plaintiffs, **3:2**
rebutting fraud-on-the-market theory,
11A:17.10
rebutting presumption of reliance,
11A:17.40
selection of class representative, **3:4**
settlement process, **3:7**
Complaint under PSLRA, model com-
plaint, **3:20, 3:21**

**PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995—Cont'd**

Congressional intent, loss causation, **11A:4**
 Construction and interpretation, loss causation. Loss causation, below
 Corporate finance theory, loss causation, **11A:8**
 Damages, generally, **3:13**
 Damages formula, **3:14.30 to 3:14.50**
 Decision of Supreme Court
 Dura Pharmaceuticals case, consequences, **11A:9 to 11A:12**
 Halliburton case, loss causation and class certification, **11A:17.30**
 Dual inquiry test of Ninth Circuit, pleading scienter after Tellabs, **3:11.130**
 Dura Pharmaceuticals case, generally, **11A:1**
 Economic loss, private securities fraud litigation, **11A:7, 11A:8**
 Eighth Circuit, loss causation, **11A:12.90**
 Eleventh Circuit, loss causation, **11A:12.120**
 Enron scandal and laxity, **4:4**
 Expert witnesses, damages formula, **3:14.50**
 Fair share rule of proportionate liability, **3:14**
 Federal circuits, uncertain loss causation issues not reached by Court in Dura Pharmaceuticals, **11A:11.1**
 Fifth Circuit, loss causation, **11A:12.60**
 Fourth Circuit, loss causation, **11A:12.50**
 Fraud on the market theory, limitation of scope in Dura Pharmaceuticals court decision, **11A:9**
 Fraud-on-the-market theory, loss causation, **11A:9, 11A:15.10**
 Institutional investors, class actions, **3:3, 3:6**
 Joint and several liability for knowing wrongdoing, **3:14.10**
 Language of PSLRA, Supreme Court's interpretation, **11A:2**
 Legislative history, loss causation, **11A:3**

**PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995—Cont'd**

Likely impact of "at least as likely" standard, **3:11.80**
 Limitation of scope in Dura Pharmaceuticals court decision, **11A:9**
 Loss causation
 generally, **3:12, 11A:1 et seq.**
 appropriate theories of loss, **11A:15**
 circuit survey, **11A:12.10 to 11A:12.120**
 class certification, **11A:17 et seq., 11A:18, 24:14, 24:15**
 common law fraud, **11A:20**
 congress' carefully designed structure of PSLRA and federal securities laws, **11A:5**
 congressional intent supporting, **11A:4**
 corporate finance theory, **11A:8**
 decision of Court in Dura Pharmaceuticals case, consequences of, **11A:9 to 11A:11**
 Dura Pharmaceuticals case, generally, **11A:1**
 economic loss, private securities fraud litigation, **11A:7, 11A:8**
 Eighth Circuit, **11A:12.90**
 Eleventh Circuit, **11A:12.120**
 event studies, **11A:16**
 evidence, **3:12.10, 11A:16**
 expert testimony, **11A:16**
 Fifth Circuit, **11A:12.60**
 First Circuit, **11A:12.20**
 Fourth Circuit, **11A:12.50**
 fraud-on-the-market theory, **11A:9, 11A:15.10, 11A:17.10, 11A:17.20**
 language of PSLRA, Supreme Court's interpretation, **11A:2**
 legislative history, **11A:3**
 limitation of scope in Dura Pharmaceuticals court decision, **11A:9, 11A:11**
 materialization of risk theory, **11A:15.20**
 Ninth Circuit, **11A:12.100**
 pleading, **3:12.10, 11A:13**

**PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995—Cont’d**

Loss causation—Cont’d
 policy concerns of Supreme Court in
 Dura Pharmaceuticals case, **11A:6**
 post-Dura Pharmaceuticals decision, **11A:14 et seq.**
 proving, **11A:16**
 proxy fraud, **17:6**
 rebutting fraud-on-the-theory, **11A:17.10**
 regression analyses, **11A:16**
 risk free assurances theory, **11A:15.30**
 SEC actions, **11A:20**
 Second Circuit, **11A:11.1, 11A:12.30**
 Section 11 and Section 12 claims, **11A:19**
 Seventh Circuit, **11A:12.80**
 Sixth Circuit, **11A:12.70**
 standards imposed by Court, satisfying, **11A:10**
 Supreme Court’s decision, **11A:17.30**
 Supreme Court’s interpretation, generally, **11A:1 et seq.**
 Tenth Circuit, **11A:12.110**
 theories of loss, **11A:15**
 Third Circuit, **11A:12.40**
 uncertain loss causation issues not reached by Court in Dura Pharmaceuticals, **11A:11 to 11A:11.2**
Materiality, “plausible” allegation, **11A:17.40**
Materialization of risk theory, **11A:15.20**
Material misstatement or omissions, pleadings, **3:9**
Meritless litigation, sanctions for, **3:19**
Model complaint under PSLRA, **3:20, 3:21**
Motive and opportunity as independent method to establish scienter, **3:11.120**
Ninth Circuit
 dual inquiry test, pleading scienter after Tellabs, **3:11.130**
 loss causation, **11A:12.100**
Oral statements, safe harbor, **3:17**

**PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995—Cont’d**

Pleading loss causation under the PSLRA, **11A:13**
Pleadings
 generally, **3:9 et seq.**
 loss causation, above
 Scienter, pleading after Tellabs, below
Policy concerns of Supreme Court in Dura Pharmaceuticals case, **11A:6**
Post-Dura developments
 generally, **11A:12**
 forward looking incentives, **10:29**
 loss causation after Dura, **11A:14**
 Section 11 and Section 12 claims, **11A:19**
Presumption of reliance, rebutting, class actions, **11A:17.40**
Professional and lead plaintiffs, class actions, **3:2**
Proportionate liability and trial practice, **3:14.20**
Proving loss causation, **3:12.10**
Recklessness as independent method to establish scienter, **3:11.120**
Regression analyses, loss causation, **11A:16**
Reliance, rebutting presumption in class action, **11A:17.40**
Rule 10b-5, forward looking incentives, **10:28**
Safe harbor, **3:15 to 3:18**
Sanctions for abusive litigation, **3:19**
Scienter, pleading after Tellabs
 generally, **3:11.100**
 award of draw to plaintiffs, **3:11.110**
 draw awarded to plaintiffs, **3:11.110**
 dual inquiry test of Ninth Circuit, **3:11.130**
 incorporation by reference, **3:11.152**
 independent methods to establish scienter, **3:11.120**
 judicial notice, **3:11.152**
 motive and opportunity as independent method to establish scienter, **3:11.120**
 recklessness as independent method to establish scienter, **3:11.120**

PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995—Cont’d

Second Circuit, loss causation
 circuit survey, **11A:12.30**
 uncertain loss causation issues not
 reached by Court in Dura
 Pharmaceuticals, **11A:11.1**

Selection of class representative, **3:4**

Settlement
 class actions, process, **3:7**
 NERA and cornerstone research
 statistics, **4:3**
 reduction, **3:14.30**

Seventh Circuit
 application of PSLRA, **3:11.50**
 confidential sources approval, **3:11.40**
 historical context of PSLRA, **3:11.30**
 loss causation, **11A:12.80**
 opinion, **3:11.20**
 remand, **3:11.90**

Sixth Circuit, loss causation, **11A:12.70**

Standards
 loss causation, **11A:10**
 pleadings, **3:11**

State of mind, pleadings, **3:10**

Supreme Court
 competing inferences and “at least as
 likely” standard, **3:11.70**
 interpretation of loss causation. Loss
 causation, below
 likely impact of “at least as likely”
 standard, **3:11.80**
 opinion, **3:11.60**
 Tellabs case, guidance on pleading
 scienter, **3:11.05**

Tellabs case, **3:11.05, 3:11.10**

Tenth Circuit, loss causation,
11A:12.110

Theories of loss, loss causation, **11A:15**

Third Circuit, loss causation, **11A:12.40**

Trial practice, **3:14.20**

Written statements, safe harbor, **3:17**

PRIVITY

Rule 10b-5, Fifth Circuit, **14:25**

PROFITS OF DEFENDANT

Rule 10b-5. See **Rule 10b-5** (this index)

PROFITS OF DEFENDANT—Cont’d

Sarbanes-Oxley Act, private action for
 profits—Section 304

PROPORTIONATE LIABILITY

Private Securities Litigation Reform Act
 of 1995, **3:14.20**

PROSPECTUS

Forced seller doctrine and Section 11
 and Section 12 claims, **14A:2**
 Material misrepresentations, Section 11
 and Section 12 claims, **14A:1,**
14A:2

PROTECTION ORDER

Scienter, **24:54.30**

PROVISIONAL REMEDIES

Generally, **23:5**

PROXIMATE CAUSE

Securities fraud⁸²¹⁷s historic lack of a
 purchaser-seller requirement, **22:3**

PROXY FRAUD

Generally, **17:1 et seq.**
 Hidden agenda in Virginia Bankshares,
17:5
 History of Section 14(a) actions, **17:2**
 Loss causation, **17:6**
 Virginia Bankshares, **17:3 to 17:5**

PROXY SOLICITATION

Interference with market for corporate
 control, **16:2**

PSLRA

Private Securities Litigation Reform Act
 of 1995. See **Private Securities**
Litigation Reform Act of 1995
 (this index)

PUBLICATION

Class actions, settlements, **25:2**

PUNITIVE DAMAGES

Racketeer influenced and corrupt
 organizations, **22:14**
 Rule 10b-5, **14:66**

**RACKETEER INFLUENCED AND
 CORRUPT ORGANIZATIONS**

Generally, **22:1 et seq., App 3**

INDEX

RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS

—Cont'd

- Arbitration, **22:12 to 22:14**
- Attorneys' fees, **22:9**
- Costs, **22:9**
- Equitable relief, **22:9**
- Historical use of RICO securities fraud,
22:2
- Measure of damages, **22:5**
- Punitive damages, securities arbitration,
22:14
- Securities fraud, **22:1**
- Securities fraud8217s historic causation
requirement, **22:4**
- Securities fraud8217s historic lack of a
purchaser- seller requirement, **22:3**
- State common law damages, **22:10**
- State-law RICO equivalents, **22:8**
- State statutory damages, **22:11**
- The 8220criminal conviction8221
exception, **22:7**
- The PSLRA8217s RICO bar, **22:6**

“REAL TIME” DISCLOSURES

- Sarbanes-Oxley Act, SEC review of
disclosures—Section 409, **5A:18**

REASONABLENESS

- Attorneys' fees in class action, agreed-
upon fees, **25:4.30**

REBUTTAL

- Class actions
 - fraud-on-the-theory, **11A:17.10**
 - “mismatch” defense, **24:13.30**
 - reliance, presumption of, **11A:17.40,**
24:13.30
- Rule 10b-5, rebuttal of fraud-on-the-
market theory, **10:30.15**

RECEIVERSHIP

- Generally, **23:4**

RECKLESSNESS

- Pleading scienter after Tellabs, indepen-
dent method to establish scienter,
3:11.120

RELIABILITY

- Event studies in securities fraud litiga-
tion, **25B:5**

RELIANCE

- Class action, rebutting presumption,
11A:17.40, 24:13.30
- Insider trading, Stoneridge decision,
15:10
- Rule 10b-5, **10:30, 10:30.50**

REMOVAL

- Securities Litigation Uniform Standards
Act of 1998, **5:12**

REORGANIZATION

- Sarbanes-Oxley Act of 2002, bankruptcy
and securities fraud, **5D:2**

REPORTING

- Implied actions and remedies, Section
12(b) and (f) of Securities
Exchange Act of 1934, **19:6**
- Sarbanes-Oxley Act, disclosure
reports—Section 401, **5A:13, 5B:7**

RESCISSION

- Instructions to jury, Section 10(b) of
Securities Exchange Act of 1934,
24:48
- Interference with market for corporate
control, **16:5**
- Rule 10b-5. See **Rule 10b-5** (this index)

RESCISSORY REMEDIES

- Proxy fraud, **17:6**

RESEARCH

- Class actions under PSLRA, statistics,
4:3

RESERVES

- Section 11 and Section 12, Securities
Act of 1933, misrepresentation of
loan loss reserves in registration
statements, **14A:1**

RETALIATION

- Informants: Sarbanes-Oxley Act, no
retaliation against informants—
Section 1107, **5A:21**
- Whistleblower protection, Sarbanes-
Oxley Act—Section 806, **5A:20**

RETROACTIVITY

- Rule 10b-5, **9:16 et seq.**

RICO

Racketeer influenced and corrupt organizations. See **Racketeer Influenced and Corrupt Organizations** (this index)

RULE 10b-5

Generally, **9:1 et seq., 10:1 et seq., 11:1 et seq., 12:1 et seq., 13:1 et seq., 14:1 et seq.**

Abandonment of loss causation, **11:9**

Aiding and abetting, constitutional law, **9:8**

American Pipe, tolling, **9:20.40**

Analysis of availability of damages, **12:11**

Analysts, fraud-on-the-market theory, **10:30.10**

Artificial inflation, fraud on the market and, **11:11**

Auction rate securities and market manipulation, **10:31.90**

Availability of damages, analysis, **12:12**

Benefit of the bargain measure of damages, **13:3, 14:65**

Causation. Loss causation, below

Circuit courts, **10:13 et seq., 10:31 et seq., 14:1 et seq.**

Circuit split

“fraud-created-the-market” theory, **10:31 et seq.**

liability under Rule 10b-5, **10:14 et seq.**

Class certification, rebuttal of fraud-on-the-market theory, **10:30.15**

Common law

generally, **12:10**

contribution, **20:22 to 20:24**

fraud, loss causation, **11:7**

Conclusion, **11:12**

Conduct rendered unlawful by Rule 10b-5, **10:6**

Congressional action, contribution, **20:15**

Congressional intent, contribution, **20:12**

Congressional response to Lampf, **9:16.10**

Congressional response to Morrison decision, **10:2.60**

RULE 10b-5—Cont’d

Connection with purchase or sale, **10:3**

Consequential damages. Special or consequential damages, below

Constitutional law

generally, **9:4 et seq.**

aiding and abetting, **9:8**

consequences of exercise of judicial power, **9:6**

contribution, implied right to, **9:7**

judicial creation and perpetuation of private right of action, **9:5, 9:6, 9:9**

Section 27A, **9:16.10**

uncertain origins of implied remedy, **9:4**

Contract cases, contribution, **20:17**

Contract model, **9:11**

Contribution

generally, **20:9 et seq.**

common law, **20:22 to 20:24**

congressional action, **20:15**

congressional intent, **20:12**

constitutional law, **9:7**

contract cases, **20:17**

distinction between implied and express victims’ remedies, **20:25**

fleshing out victim’s claim, **20:24**

holding and analysis of Supreme Court, **20:26**

independent federal regulatory scheme, **20:18**

legislative scheme, **20:16**

Northwest Airlines and Texas Industries, **20:19**

policy considerations, **20:13**

strongest arguments, **20:11 et seq.**

well established right, **20:14 et seq.**

“Cover” measure of damages, Tenth Circuit, **14:52**

Definition of theories, Supreme Court, **13:2**

Direct market repercussion theory, Second Circuit, **14:10**

Disclosure, materiality, **10:27.60**

Disgorgement

generally, **14:62**

First Circuit, **14:4**

Second Circuit, **14:11**

INDEX

RULE 10b-5—Cont'd

District of Columbia Circuit
generally, **10:25, 14:57 to 14:59**
liability under Rule 10b-5, **10:25**
rescissionary relief, **14:58**
valuation limits, **14:59**
Divergent court approaches
“fraud-created-the-market” theory,
10:31 et seq.
liability under Rule 10b-5, **10:14 et seq.**
Dura’s impact on securities fraud sentences, **11:11.10**
Duty to disclose, materiality, **10:27.60**
Eighth Circuit
generally, **10:21, 14:42 to 14:45**
calculation of damages, **14:43**
liability under Rule 10b-5, **10:21**
materiality of misstatement or omission, **14:45**
valuation date, **14:44**
Election of rescission or rescissionary damages, Tenth Circuit, **14:51**
Elements of action, **9:13**
Eleventh Circuit
generally, **10:24, 14:54 to 14:56**
fraud-created-the-market theory,
10:31.30
liability under Rule 10b-5, **10:24**
limitations on damages, **14:56**
rescission, **14:55, 14:56**
Event studies in securities fraud litigation, **25B:6**
Express remedies, limitations from,
12:5, 12:6
External market forces, Seventh Circuit,
14:39
Fiduciary duty, breach of, **10:7**
Fifth Circuit
generally, **10:18, 14:23 to 14:28**
fraud-created-the-market theory,
10:31.20
liability under Rule 10b-5, **10:18**
limitations on general rule applicability, **14:24**
materiality, role in damage measurement, **14:27**
privity, **14:25**
rescission, **14:26**

RULE 10b-5—Cont'd

Fifth Circuit—Cont'd
special or consequential damages,
14:28
First Circuit
generally, **10:14, 14:2 to 14:4**
exceptions, **14:3**
liability under Rule 10b-5, **10:14**
unjust enrichment or engorgement,
14:4
Five year statute of repose, **9:19**
Fleshing out victim’s claim, contribution, **20:24**
Foreign cubed cases, extraterritorial application of Rule 10b-5, **10:2.50, 10:2.60, 27:10**
Forfeitures, tolling, **9:20.30**
Fourth Circuit
generally, **10:17, 14:17 to 14:22**
discretion, factors in applying, **14:18**
liability under Rule 10b-5, **10:17**
materiality of actions or omissions,
14:20
qualified profit measure of damages,
14:21
rescission, rejection of, **14:19**
rescissionary measure of damages,
14:22
“Fraud-created-the-market” theory,
10:30
generally, **10:31**
endorsement by circuit courts,
10:31.10 to 10:31.40
reconciling circuit split, **10:31.80**
regulatory process, reliance on,
10:31.35
rejection by circuit courts, **10:31.55 to 10:31.80**
reliance, **10:31.35**
Fraud-on-the-market theory
actions against analysts, **10:30.10**
artificial inflation, **11:11**
measure of damages, uniformity,
13:16
rebuttal during class certification,
10:30.15
Implied right to contribution. Contribution, above

RULE 10b-5—Cont'd

- Independent federal regulatory scheme, contribution, **20:18**
- Jurisdictional means, **10:2**
- Jurisdictional model, **9:12**
- Legislative intent, materiality, **13:10, 13:11**
- Loss causation
 - generally, **11:1 et seq.**
 - abandonment of loss causation, **11:9**
 - arguments supporting loss causation, **11:4 et seq.**
 - common law fraud, **11:7**
 - denial of all recovery, **11:3**
 - evolution, **11:2**
 - life after loss causation, **11:10**
 - regulatory scheme, analogies to, **11:5**
 - Supreme Court declarations, **11:6**
 - unlimited exposure, potential for, **11:8**
- Loss causation, fraud on the market and artificial inflation, **11:11**
- Lower courts, **10:13 et seq., 14:1 et seq.**
- Market manipulation and auction rate securities, **10:31.90**
- Materiality
 - generally, **12:6 to 12:9, 13:7 et seq., 14:67**
 - duty to disclose, **10:27.60**
 - Eighth Circuit, **14:45**
 - Fifth Circuit, **14:27**
 - Fourth Circuit, **14:20**
 - Ninth Circuit, **14:49**
 - Second Circuit, **14:7**
 - Seventh Circuit, **14:34, 14:39, 14:40**
 - shareholder proposals, **10:27.80**
 - “statistically significant” test, **10:27.50**
 - the 82168216bespeaks caution82178217 doctrine, **10:27**
 - Third Circuit, **14:16**
- Misappropriation, **10:11**
- Morrison, evolution of and extraterritorial reach of Rule 10b-5, **10:2.70**
- Ninth Circuit
 - generally, **10:22, 14:46 to 14:49**
 - calculation of value, **14:48**
 - liability under Rule 10b-5, **10:22**
 - materiality, quantification of, **14:49**

RULE 10b-5—Cont'd

- Ninth Circuit—Cont'd
 - rescission, **14:47**
- Objectification of culpability, **10:12**
- Out-of-pocket, Supreme Court, **13:4 to 13:6**
- Policy considerations, contribution, **20:13**
- Presumptions of reliance, **10:30**
- Private Securities Litigation Reform Act of 1995, forward looking incentives, **10:28, 10:29**
- Privity, Fifth Circuit, **14:25**
- Profits of defendant
 - generally, **14:63**
 - Fourth Circuit, **14:21**
 - Second Circuit, **14:9**
 - Third Circuit, **14:14**
- Public disclosure and materiality, Second Circuit, **14:10**
- Puffery, **10:27.70**
- Punitive damages, **14:66**
- Purpose, statute of limitations, **9:15**
- Rebuttal of fraud-on-the-market theory, **10:30.15**
- Reliance
 - fraud-created-the-market theory, **10:30**
 - fraud-on-the-market theory, **10:30.50, 10:31.35**
- Remedial powers, **12:2 to 12:4**
- Resale price measure of damages, Second Circuit, **14:8**
- Rescission
 - generally, **14:64**
 - District of Columbia Circuit, **14:58**
 - Eleventh Circuit, **14:55, 14:56**
 - Fifth Circuit, **14:26**
 - Fourth Circuit, **14:19, 14:22**
 - materiality, **13:12**
 - Ninth Circuit, **14:47**
 - Seventh Circuit, **14:35**
 - Third Circuit, **14:15**
- Retroactivity, **9:16 et seq.**
- Sarbanes-Oxley Act, statutes of limitations implications, **9:16**
- Scienter, **10:6, 10:10**
- SEC investigations
 - two year limitations period, **9:18.10**

INDEX

RULE 10b-5—Cont'd

Second Circuit

generally, **10:15, 14:5 to 14:12**
direct market repercussion theory, **14:10**
disgorgement, **14:11**
exceptions, **14:6**
extraterritorial application to foreign cubed cases, **10:2.50, 27:10**
liability under Rule 10b-5, **10:15**
materiality of misstatements or omissions, **14:7**
profit of defendant, recovery of, **14:9**
public disclosure and materiality, **14:10**
resale price measure of damages, **14:8**
Section 27A, constitutional law, **9:16.10**
Section 27(a), district court jurisdiction, **12:2**
Section 28(a) limitations on damages, **12:3, 12:4**
Securities Act of 1933, **12:5 et seq.**
Securities Exchange Act of 1934, **12:5 et seq.**
Security, **10:4**
Sentencing, Dura's impact on, **11:11.10**
Seventh Circuit
generally, **14:32 to 14:41**
congruence between rescissory and market measure of damages, **14:38**
exceptions, **14:33**
external market forces, **14:39**
fraud-created-the-market theory, **10:31.55**
liability under Rule 10b-5, **10:20**
materiality, role in damages measurement, **14:34**
materiality of nondisclosure, quantification of, **14:39, 14:40**
rescission, **14:35**
Uniform Commercial Code, analogy to, **14:36, 14:37**
Shareholder proposals, materiality, **10:27.80**
Sixth Circuit
generally, **10:19, 14:29 to 14:31**
additional relief, **14:30**

RULE 10b-5—Cont'd

Sixth Circuit—Cont'd

fraud-created-the-market theory, **10:31.70**
liability under Rule 10b-5, **10:19**
limitations upon recovery, **14:31**
Special or consequential damages
Fifth Circuit, **14:28**
Tenth Circuit, **14:53**
Standing, holder suits, **10:3.50**
“Statistically significant” test, materiality, **10:27.50**
Statute of limitations, **9:14 et seq.**
Statutory guidance, **12:1 et seq.**
Supreme Court guidance, **9:15 to 9:20.40, 13:1 et seq.**
Tellabs case, **24:58**
Tenth Circuit
generally, **10:23, 14:50 to 14:53**
consequential damages, **14:53**
“cover” measure of damages, **14:52**
election of rescission or rescissory damages, **14:51**
fraud-created-the-market theory, **10:31.30**
liability under Rule 10b-5, **10:23**
Test for implication, **9:2**
Third Circuit
generally, **10:16, 14:13 to 14:16**
fraud-created-the-market theory, **10:31.60**
liability under Rule 10b-5, **10:16**
materiality, **14:16**
profits of defendant, **14:14**
rescission, **14:15**
Threshold elements, **10:1 to 10:3**
Tippee liability, **10:9, 10:10**
Tipper liability, **10:8**
Tolling, **9:20 et seq.**
Tort law, **12:10**
Tort model, **9:10**
Two and five year limitations period, **9:17 et seq.**
retroactivity, **9:17.10**
Uniform Commercial Code, Seventh Circuit, **14:36, 14:37**
Uniformity of measure of damages under Sections 12(2) and 10(b), **13:13 to 13:16**

RULE 10b-5—Cont'd

Unjust enrichment, First Circuit, **14:4**
 Valuation date, Eighth Circuit, **14:44**
 Valuation limits, District of Columbia
 Circuit, **14:59**
 Well established right, contribution,
20:14 et seq.

RULE 26

Scienter, discoverability of identities of
 confidential witnesses, **24:54.10**

SAFE HARBOR

Private Securities Litigation Reform Act
 of 1995, **3:15 to 3:18**

SANCTIONS

Private Securities Litigation Reform Act
 of 1995, abusive litigation, **3:19**

SARBANES-OXLEY ACT (SOX)

Generally, **5A:1 to 5A:24**

Attorney-client privilege, securities
 fraud, new statutory duty to dis-
 close client confidences, **5C:3,**
5C:5

Attorneys

conduct rules for—Section 307,
5A:12
 disclosure of client confidences, new
 federal statutory duty, **5C:3**
 exposure, securities fraud after
 Sarbanes-Oxley, **5C:1 to 5C:9**
 nationalization consequences, **5C:9**
 nationalization of securities regula-
 tion, **5C:4**
 national securities law standards,
 trend toward, **5C:7**
 preemptive force, SEC attorney
 professional standards, **5C:6**
 private right of action against attorney
 for failure to blow whistle, **5C:8**
 securities fraud following Sarbanes-
 Oxley Act, **5C:1**
 whistleblowing, below
Audits and auditors
 audit committee
 generally—Section 301, **5A:7**
 financial experts—Section 407,
5A:16
 auditor-related provisions, **5A:22**

SARBANES-OXLEY ACT (SOX)

—Cont'd

Audits and auditors—Cont'd
 improper influence on audits—Sec-
 tion 303, **5A:8**
 Automatic stay, debtor-company in
 bankruptcy, **5D:3**
 Bankruptcy and securities fraud
 generally, **5D:1**
 automatic stay, **5D:3**
 claims against debtor-company while
 in bankruptcy, **5D:3**
 class proof of claims, **5D:4**
 discharge, excepting securities fraud
 claims, **5D:5**
 examiners, **5D:7**
 exceptions, **5D:5**
 forced sale, reorganization proceed-
 ings as, **5D:2**
 proof of claims, **5D:4**
 reorganization proceedings as forced
 sale, **5D:2**
 time of claim, **5D:3**
 trustees, **5D:6**
 Bonuses and profits, private action for—
 Section 304, **5B:5**
 Breach of new withdrawal and
 disclosure obligations, private
 actions against attorneys for, **5B:10**
 CEO and CFO certification require-
 ments, **5A:3, 5B:4**
 Certification
 CEO and CFO certification require-
 ments, **5A:3, 5B:4**
 Section 906 certification, **5A:4**
 Civil actions. Private civil liability
 enhancement, below
 Class proof of claims, **5D:4**
 Conflict of laws, state attorney
 confidentiality standards in conflict
 with SEC's regime, **5C:5**
 Corporate responsibility re CEO and
 CFO certification of financial state-
 ments, **5B:4**
 Criminal law, Act's reliance on, **5A:25**
 Damages
 private actions—Section 803, dam-
 ages not dischargeable, **5B:9**

SARBANES-OXLEY ACT (SOX)

—Cont'd

Discharge, excepting securities fraud claims, **5D:5**

Disclosures

- attorney's duty to disclose client confidences, **5C:3**
- disclosure report—Section 401, **5A:13, 5B:7**
- private actions against attorneys for breach of new withdrawal and disclosure obligations, **5B:10**
- rapid and current basis, disclosure on—Section 409, **5B:8**
- “real time” disclosures—Section 409, **5A:18**
- SEC review of disclosures—Section 408, **5A:17**

Examiners, bankruptcy, **5D:7**

Excepting securities fraud claims from bankruptcy discharge, **5D:5**

Financial experts, audit committee—Section 407, **5A:16**

Financial officers, ethics code—Section 406, **5A:15**

Forced sale, reorganization proceedings as, **5D:2**

Forfeiture of executive payments upon restatements—Section 304, **5A:9**

Forfeitures

- tolling
 - limitation of actions, securities fraud, **9:20.30**

Improper influence on audits—Section 303, **5A:8**

Informants, no retaliation against—Section 1107, **5A:21**

Insider trading

- pension blackout periods, trades during—Section 306, **5A:11, 5B:6**
- professional liability under Sarbanes-Oxley, **15:6**

Limitation of actions, securities fraud implied remedies, **9:15 et seq.**

- section 10(b) and SEC complaints, **9:18**
- Section 804, **5A:19, 5B:2**
- tolling, **9:20 et seq.**

SARBANES-OXLEY ACT (SOX)

—Cont'd

Loans to executive officers and directors, prohibition, **5A:6**

Management assessment of internal accounting controls—Section 404, **5A:14**

Nationalization of securities regulation, damages for attorney exposure, **5C:4**

National securities law standards, trend toward, **5C:7**

Officer and director bars—Section 305, **5A:10**

Omissions from Act, **5A:24**

Overview, **5A:2**

Political and economic environment, **5A:1**

Preemptive force, SEC attorney professional standards, **5C:6**

Private civil liability enhancement

- generally, **5B:1 to 5B:9**
- bonuses and profits, action for, **5B:5**
- breach of new withdrawal and disclosure obligations, private actions against attorneys for, **5B:10**
- corporate responsibility re CEO / CFO certifications of financial statements, **5B:4**
- damages not dischargeable—Section 803, **5B:9**
- fraud, statute of limitations—Section 804, **5B:2**
- new, private causes of action, **5B:3**
- pension fund blackouts, insider trading during—Section 306, **5B:6**
- periodic reports, private actions based on disclosures in—Section 306, **5B:7**
- rapid and current basis, disclosure on—Section 409, **5B:8**
- statute of limitations for fraud—Section 804, **5B:2**

Private right of action against attorneys failing to blow the whistle, **5C:8**

Proof of claims, bankruptcy and securities fraud, **5D:4**

Reorganization proceedings as forced sale, **5D:2**

SARBANES-OXLEY ACT (SOX)

—Cont'd

- SEC review of disclosures—Section 408, **5A:17**
- Section 906 certification, **5A:4**
- Securities fraud
 - for other aspects of securities fraud, see specific entries in this topic
 - attorney exposure to damages. Damages, above
 - statute of limitations. Limitation of actions, above
- Shorter Section 16 reporting deadline, **5A:5**
- Significance of Act, **5A:23**
- Statute of limitations. Limitation of actions, above
- Tolling
 - limitation of actions, securities fraud, **9:20 et seq.**
- Trustees, bankruptcy, **5D:6**
- Whistleblowing
 - attorney exposure to damages
 - federal common law duty to blow whistle in re securities fraud, **5C:2**
 - private right of action, failure to blow whistle on securities fraud, **5C:8**
 - whistleblower protection—Section 806, **5A:20**
- Withdrawal, private actions against attorneys for breach of new withdrawal and disclosure obligations, **5B:10**

SCIENTER

- Availability of work-product protection, **24:54.20**
- Collective scienter, **24:55**
- Confidential sources
 - circuit survey, **24:53.10**
 - discovery, **24:54, 24:54.10**
 - documents from, **24:53.20**
 - pleading, **24:52.50, 24:53, 24:55**
 - private investigators, **24:53.30**
 - Rule 26 discoverability of identities, **24:54.10**
- “Core operations” inference
 - generally, **24:56**

SCIENTER—Cont'd

- “Core operations” inference—Cont'd
 - allegations, bolstering with core operations inference, **24:56.20**
 - imputing scienter on core operations inference alone, **24:56.10**
 - misconstruing inference, **24:56.40**
 - reconciling approaches, **24:56.50**
- Inference, “core operations,” **24:56 et seq.**
- Obtaining order of protection, **24:54.30**
- Private Securities Litigation Reform Act of 1995** (this index)
- Red flags, **24:6**
- Rule 10b-5, **10:6, 10:10**
- Rule 26 discoverability of identities of confidential witnesses, **24:54.10**
- Tellabs analysis
 - availability of work-product protection, **24:54.20**
 - circuit survey, use of confidential witnesses, **24:53.10**
 - collective scienter, **24:55**
 - discovery of confidential witnesses, **24:54, 24:54.10**
 - establishing, **24:52**
 - Fifth Circuit, **24:10**
 - First Circuit, **24:8**
 - obtaining order of protection, **24:54.30**
 - pleading, **24:4, 24:7 to 24:11, 24:52.50, 24:53, 24:55**
 - protection order, **24:54.30**
 - Rule 26 discoverability of identities of confidential sources, **24:54.10**
 - Seventh Circuit, **24:11**
 - Third Circuit, **24:9**
 - use of confidential witnesses, **24:53, 24:53.10**
 - work-product protection, **24:54.20**
- Work-product protection, **24:54.20**

SCOPE OF FEDERAL SECURITIES REGULATION

- Generally, **5:1 to 5:15**
- Internet
 - electronic delivery, **5:14**
 - securities fraud, **5:15**
- Preemptive course, **5:1**

INDEX

SCOPE OF FEDERAL SECURITIES REGULATION—Cont'd

Securities Litigation Uniform Standards Act of 1998 (this index)

SECONDARY LIABILITY

Insider trading. See **Insider Trading** (this index)

SECTION 10(b), SECURITIES EXCHANGE ACT OF 1934

Event studies, **25B:6**

Insider trading, Stoneridge decision, **15:12**

Instructions to jury. See **Instructions to Jury** (this index)

Statutes of limitations, **9:18**

Tellabs case, **24:58**

SECTION 11, SECURITIES ACT OF 1933

Generally, **6:1 et seq.**

Causation defense, lack of, **6:25**

Common law remedies, inadequacy of, **6:7**

Declining market, **6:21**

Defenses, **6:4**

Elements of liability, **6:3**

Event studies, **25B:8**

False statement of opinion, pleading under Section 11, **6:3.20**

Forced seller doctrine and Section 11 claims, **14A:2**

Formula for damages

generally, **6:9 et seq.**

amended formula, **6:11**

criticism, **6:9**

original formula, **6:10**

plaintiff keeps security, **6:12**

plaintiff sells security before suit, **6:13**

plaintiff sells security during suit, **6:14**

summary of damage alternatives, **6:15 to 6:18**

value, **6:17, 6:18**

Good will, misrepresentation in registration statements, **14A:1**

Influenced market, **6:23**

SECTION 11, SECURITIES ACT OF 1933—Cont'd

Instructions to jury

generally, **24:35 et seq.**

limit on recovery, **24:40**

plaintiff retains stock, **24:36**

plaintiff sells security before suit, **24:37**

plaintiff sells security during litigation, **24:38**

special interrogatories, **24:41**

underwriter, defendant as, **24:39**

Legislative history of civil remedies, **6:6**

Liability, generally, **6:2 to 6:4.10**

Loan loss reserves, misrepresentation in registration statements, **14A:1**

Loss causation, **11A:18, 11A:19, 12:5.05**

Make plaintiff whole, **6:20**

Misrepresentation of good will and loan loss reserves in registration statements, **14A:1**

Mutual funds, fraud against, **6:4.10**

Negative causation, proof of, **6:28**

Overview of violations, **6:2 et seq.**

Prospectus

forced seller doctrine and Section 12 claims, **14A:2**

material misrepresentations, private action, **14A:2**

private action for material misrepresentations, **14A:2**

Proviso for damages

generally, **6:25 et seq.**

causation defense, lack of, **6:25**

conclusion, **6:30**

judicial guidance, **6:27**

judicial restraints, **6:29**

negative causation under Section 11, **6:28, 6:31**

proof of negative causation, **6:28**
value, **6:26**

Purposes of civil remedies, **6:5 to 6:8**

Registration statements

good will, misrepresentation, **14A:1**

loan loss reserves, misrepresentation, **14A:1**

Rising market, **6:22**

Special interrogatories, **24:41**

SECTION 11, SECURITIES ACT OF 1933—Cont'd

Summary of damage alternatives, **6:15 to 6:18**

Supplement to common law, design as, **6:8**

Theory of damages

generally, **6:19 et seq.**

contrast with traditional damage formula, **6:19**

damage alternatives, **6:24**

declining market, **6:21**

influenced market, **6:23**

make plaintiff whole, **6:20**

rising market, **6:22**

Underwriters (this index)

Value, **6:17, 6:18, 6:26**

SECTION 12, SECURITIES ACT OF 1933

Forced seller doctrine and Section 12 claims, **14A:2**

Good will, misrepresentation in registration statements, **14A:1**

Instructions to jury, **24:42 to 24:44**

Loan loss reserves, misrepresentation in registration statements, **14A:1**

Loss causation, **11A:19, 12:5.05**

Misrepresentation of good will and loan loss reserves in registration statements, **14A:1**

Prospectus

forced seller doctrine and Section 12 claims, **14A:2**

material misrepresentations, private action, **14A:2**

private action for material misrepresentations, **14A:2**

Registration statements

good will, misrepresentation, **14A:1**

loan loss reserves, misrepresentation, **14A:1**

SECTION 16, SECURITIES EXCHANGE ACT OF 1934

Generally, **8:6 et seq.**

Dividends, **8:11**

Employee stock options, **8:10**

Expenses, **8:13**

Interest, **8:12**

SECTION 16, SECURITIES EXCHANGE ACT OF 1934

—Cont'd

Matching, **8:9**

Measure of damages, **8:8**

Purchase or sale price in noncash transactions, **8:14**

Statute of limitations, **8:14.50**

SECTION 17(A)

Implied actions and remedies, **19:1, 19:2**

SECTION 27A

Rule 10b-5, constitutional law, **9:16.10**

SECTION 27(A)

Rule 10b-5, district court jurisdiction, **12:2**

SECTION 28(A)

Rule 10b-5, limitations on damages, **12:3, 12:4**

SECURITIES ACT OF 1933

Generally, **App 1**

Rule 10b-5. See **Rule 10b-5** (this index)

Section 11, Securities Act of 1933. See **Section 11, Securities Act of 1933** (this index)

Section 12, Securities Act of 1933. See **Section 12, Securities Act of 1933** (this index)

SECURITIES AND EXCHANGE COMMISSION

Aiding and abetting enforcement actions, effect of Stoneridge decision, **15:17**

Complaints, Sarbanes-Oxley Act Section 10(b), **9:16**

Sarbanes-Oxley Act, SEC review of disclosures—Section 408, **5A:17**

SECURITIES EXCHANGE ACT OF 1934

Generally, **8:1 et seq., App 2**

Causation, **8:4, 8:16**

Listed stock manipulations, **8:3 to 8:5**

Misstatement in filed reports, **8:15, 8:16**

Overview of act, **8:2**

Rule 10b-5. See **Rule 10b-5** (this index)

INDEX

SECURITIES EXCHANGE ACT OF 1934—Cont'd

Section 9(e), **8:3 to 8:5**

Section 10(b), Securities Exchange Act of 1934. See **Section 10(b), Securities Exchange Act of 1934** (this index)

Section 16, Securities Exchange Act of 1934. See **Section 16, Securities Exchange Act of 1934** (this index)

Section 18, **8:15, 8:16**

SECURITIES FRAUD

Confidential witnesses, pleading, **24:53**
Sarbanes-Oxley Act (SOX) (this index)

SECURITIES FRAUD LITIGATION

Event studies, **25B:1 et seq.**

SECURITIES FRAUD^{8217S} HISTORIC CAUSATION REQUIREMENT

Racketeer influenced and corrupt organizations, **22:4**

SECURITIES LITIGATION UNIFORM STANDARDS ACT OF 1998

Generally, **5:2 to 5:13**

Amendment by plaintiff, **5:10**

“Best execution” claims, **5:8.30**

Class Actions (this index)

Covered securities, **5:7**

Direct rather than derivative actions, **5:8**

Discovery stay, **5:13**

Dismissal, **5:9**

Federal class actions in state court, **5:8.70**

Language of act, **5:3**

Plaintiff’s ability to amend, **5:10**

Preclusion, **5:4 to 5:8.70**

Procedural devices, **5:11 to 5:13**

Removal, **5:12**

Scope of Federal Securities Regulation (this index)

Scope of preclusion, **5:4 to 5:8.70**

SECURITY

Class actions, security for costs, **25:5**

Defined, **1:5**

Laws, generally, **1:3**

SECURITY—Cont'd

Rule 10b-5, **10:4**

SELECTION OF INTERIM LEAD PLAINTIFF

Advertising ⁸²²⁰investigations,⁸²²¹ solicit lead plaintiffs, **25:1.40**

Monitoring arrangements, institutional investors, **25:1.30**

⁸²²⁰Pay to play⁸²²¹ arrangements, **25:1.20**

SELF-REGULATORY ORGANIZATIONS (SROs)

Enforcement of securities laws, role of SROs, **26A:2**

FiINRA and the role of SROs in enforcement of securities laws, **26A:2**

SENTENCING

Rule 10b-5, **11:11.10**

SETTLEMENT

Class actions, **25:2, 25:3**

Contribution, effect on, **20:5, 20:27**

Independent approval, **25:3.10**

Non-lead counsel, issues with and other actors seeking payment from the common fund, **25:4.40**

Private Securities Litigation Reform Act of 1995 (this index)

SEVENTH AMENDMENT

Event studies in securities fraud litigation, **25B:2**

SPECIAL DAMAGES

Rule 10b-5. See **Rule 10b-5** (this index)

SPECIAL INTERROGATORIES

Section 11, Securities Act of 1933, **24:41**

STANDING

Rule 10b-5, holder suits, **10:3.50**

STATE COURTS

Federal class actions in state court, **5:8.70**

Insider trading, Stoneridge decision, **15:19**

STATE-LAW RICO EQUIVALENTS

Racketeer influenced and corrupt organizations, **22:8**

STATE OF MIND

Private Securities Litigation Reform Act of 1995, pleadings, **3:10**

“STATISTICALLY SIGNIFICANT”

Rule 10b-5, materiality test, **10:27.50**

STATISTICS

Class actions under PSLRA, NERA and cornerstone research, **4:3**

STATUTE OF LIMITATIONS

Limitation of actions. See **Limitation of Actions** (this index)

STONERIDGE CASE

Insider Trading (this index)

SUBROGATION

Generally, **26:1, 26:3**

SUMMARY EXHIBITS

Instructions to jury, **24:26, 24:27**

SUMMARY JUDGMENT

Generally, **24:17**

Event studies in securities fraud litigation, **25B:9**

SUPREME COURT

Insider Trading (this index)

Material facts, statistical significance, **18:5**

Private Securities Litigation Reform Act of 1995 (this index)

Rule 10b-5, **9:15 to 9:20.40**

SWAPS

Credit default swaps under FINFA rules, **26A:1**

Dodd-Frank, antifraud measures, **5E:2**

TELLABS CASE

Allegations, PSLRA, **3:11.10**

Circuit survey, use of confidential witnesses, **24:53.10**

Collective scienter, **24:55**

Confidential sources and pleading, **24:52.50 et seq.**

TELLABS CASE—Cont’d

Discovery and confidential sources, **24:54, 24:54.10**

Establishing scienter, **24:52**

Expansion beyond § 10b and Rule 10b-5 actions, **24:58**

Fraud by hindsight, **24:57**

Group pleading, **24:55**

Motive, pleading scienter, **24:52.50**

Opportunity, pleading scienter, **24:52.50**

Private Securities Litigation Reform Act of 1995, **3:11.05, 3:11.10**

Recklessness, pleading scienter, **24:52.50**

Rule 10b-5, **24:58**

Scienter

availability of work-product protection, **24:54.20**

circuit survey, use of confidential witnesses, **24:53.10**

collective scienter, **24:55**

confidential witnesses, **24:53, 24:53.10**

core operations inference, **24:56 et seq.**

discovery of confidential witnesses, **24:54, 24:54.10**

establishing, **24:52**

Fifth Circuit, **24:10**

First Circuit, **24:8**

incorporation by reference, **3:11.152**

inference, core operations, **24:56 et seq.**

judicial notice, **3:11.152**

motive, pleading scienter, **24:52.50**

obtaining order of protection, **24:54.30**

opportunity, pleading scienter, **24:52.50**

pleading scienter, **24:4, 24:7 to 24:11, 24:52, 24:52.50, 24:55**

protection order, **24:54.30**

recklessness, pleading scienter, **24:52.50**

Rule 26 discoverability of identities of confidential sources, **24:54.10**

Seventh Circuit, **24:11**

Third Circuit, **24:9**

work-product protection, **24:54.20**

INDEX

TELLABS CASE—Cont'd

Section 10(b) of Securities Exchange
Act of 1934, **24:58**
Supreme Court, guidance on pleading
scienter, **3:11.05**

TENDER OFFERS

Interference with market for corporate
control, **16:3, 16:4**

THE 8220CRIMINAL CONVICTION8221 EXCEPTION

Racketeer influenced and corrupt
organizations, **22:7**

THIRD CIRCUIT TASK FORCE

Class actions, **25:7**

TIPPEE LIABILITY

Rule 10b-5, **10:9, 10:10**

TIPPER LIABILITY

Rule 10b-5, **10:8**

UNDERWRITERS

Actions against, **6:3.10, 24:39**
Liability for shares distributed to public,
6:32

UNDERWRITERS—Cont'd

Section 11, Securities Act of 1933,
6:3.10, 6:32, 24:39

UNIFORM COMMERCIAL CODE

Rule 10b-5, Seventh Circuit, **14:36,**
14:37

UNJUST ENRICHMENT

Rule 10b-5, First Circuit, **14:4**

VALUE

Rule 10b-5, **14:44, 14:59**
Section 11, Securities Act of 1933, **6:17,**
6:18, 6:26

WHISTLEBLOWING

Dodd-Frank, **5E:3**
Sarbanes-Oxley Act (SOX) (this index)

WITNESSES

Confidential, securities fraud pleadings,
24:53

WORK-PRODUCT PROTECTION

Scienter, **24:54.20**